{"id":13924,"date":"2022-08-25T12:00:28","date_gmt":"2022-08-25T10:00:28","guid":{"rendered":"https:\/\/www.bm-t.de\/2021\/bmt-investee-partner-oncgnostics-enters-the-chinese-market\/"},"modified":"2026-06-10T20:52:26","modified_gmt":"2026-06-10T18:52:26","slug":"bmt-investee-partner-oncgnostics-enters-the-chinese-market","status":"publish","type":"post","link":"https:\/\/www.bm-t.de\/en\/2022-en\/bmt-investee-partner-oncgnostics-enters-the-chinese-market\/","title":{"rendered":"bm|t subsidiary oncgnostics conquers the Chinese market"},"content":{"rendered":"

The screen\u00ading test for cer\u00advi\u00adcal can\u00adcer pre\u00adven\u00adtion <\/strong>Gyn\u00adTect<\/strong><\/a> is now avail\u00adable to doc\u00adtors and patients in China, the world\u2019s most pop\u00adu\u00adlous coun\u00adtry, under exclu\u00adsive license. Gyn\u00adTect was devel\u00adoped by the <\/strong>oncg\u00adnos\u00adtics GmbH<\/strong><\/a> and is already approved in Europe. It is the first prod\u00aduct of its kind that can be used for abnor\u00admal find\u00adings in China. Gyn\u00adTect can now help mil\u00adlions of women there to take treat\u00adment mea\u00adsures quickly or pre\u00advent them from being overtreated. Above all, they will receive a reli\u00adable diag\u00adno\u00adsis much faster than usual. <\/strong><\/p>\n

How Gyn\u00adTect works<\/strong><\/p>\n

The Gyn\u00adTect mol\u00ade\u00adc\u00adu\u00adlar bio\u00adlog\u00adi\u00adcal test devel\u00adoped by oncg\u00adnos\u00adtics clar\u00adi\u00adfies at an early stage whether a patient with con\u00adspic\u00adu\u00adous find\u00adings is devel\u00adop\u00ading or even already has cer\u00advi\u00adcal can\u00adcer that needs to be treated. The clar\u00adi\u00adfi\u00adca\u00adtion test detects changes in the DNA (so-called methy\u00adla\u00adtions), which only occur if cer\u00advi\u00adcal can\u00adcer is present or devel\u00adop\u00ading. To carry out the test, all that is needed is a smear test like the ones taken by a gyne\u00adcol\u00ado\u00adgist as part of reg\u00adu\u00adlar screen\u00ading. So far, Gyn\u00adTect has detected all cases of women with cer\u00advi\u00adcal cancer. <\/p>\n

How Gyn\u00adTect is used in China<\/strong><\/p>\n

\u201cWe are delighted that GeneoDx has been able to approve Gyn\u00adTect, the first DNA methy\u00adla\u00adtion-based prod\u00aduct for the early detec\u00adtion of cer\u00advi\u00adcal can\u00adcer in China. This is a great mile\u00adstone for GeneoDx, but also for all Chi\u00adnese women who can now have access to such an inno\u00adv\u00ada\u00adtive prod\u00aduct!\u201d said Xiaokai Xia, Man\u00adag\u00ading Direc\u00adtor of Shang\u00adhai GeneoDx. GeneoDx<\/a> is a sub\u00adsidiary of the Sinopharm Group. <\/a>In China, more than 100,000 new cases of can\u00adcer and almost 60,000 deaths are reported every year. Stud\u00adies have shown that around 17% of women in China test pos\u00adi\u00adtive for human papil\u00adlo\u00admavirus (HPV) dur\u00ading cer\u00advi\u00adcal can\u00adcer screen\u00adings. This cor\u00adre\u00adsponds to around 70 mil\u00adlion patients whose find\u00adings have yet to be clar\u00adi\u00adfied at great expense. This is because only a few women with an HPV infec\u00adtion develop cer\u00advi\u00adcal can\u00adcer. Gyn\u00adTect detects pre\u00adcisely these cases. <\/p>\n

<\/p>\n

Advan\u00adtages of GynTect<\/strong><\/p>\n

Gyn\u00adTect pro\u00advides fast and reli\u00adable exam\u00adi\u00adna\u00adtion results and gives affected women cer\u00adtainty just as quickly about the best way to pro\u00adceed after an abnor\u00admal pre\u00adlim\u00adi\u00adnary exam\u00adi\u00adna\u00adtion result. Risk assess\u00adment is made much eas\u00adier: on the one hand, unnec\u00ades\u00adsary oper\u00ada\u00adtions can be avoided and, on the other, the chances of suc\u00adcess\u00adful treat\u00adment mea\u00adsures can be increased. Accord\u00ading to GeneoDx, the Chi\u00adnese coop\u00ader\u00ada\u00adtion part\u00adner of oncg\u00adnos\u00adtics, the num\u00adber of refer\u00adrals for cer\u00advi\u00adcal endoscopy (col\u00adposcopy) can be reduced by more than 60% through the use of Gyn\u00adTect. In col\u00adposcopy, the cervix is exam\u00adined for abnor\u00admal\u00adi\u00adties and changes using a spe\u00adcial micro\u00adscope and pro\u00adce\u00addure. In most cases, gyne\u00adcol\u00ado\u00adgists in pri\u00advate prac\u00adtice are unable to per\u00adform this them\u00adselves. The woman con\u00adcerned must there\u00adfore wait for an appoint\u00adment at a spe\u00adcial\u00adist consultation. <\/p>\n

In addi\u00adtion to numer\u00adous EU coun\u00adtries and the Peo\u00adple\u2019s Repub\u00adlic of China, Gyn\u00adTect is already dis\u00adtrib\u00aduted in Brazil and Mex\u00adico. oncg\u00adnos\u00adtics GmbH is con\u00adstantly work\u00ading on con\u00adclud\u00ading suit\u00adable coop\u00ader\u00ada\u00adtion agree\u00adments for other coun\u00adtries worldwide. <\/p>\n

\u201cThis is another suc\u00adcess for our bm|t port\u00adfo\u00adlio and once again demon\u00adstrates the global stand\u00ading of the life sci\u00adence clus\u00adter in Jena. We are par\u00adtic\u00adu\u00adlarly pleased that oncg\u00adnos\u00adtics is already in advanced talks with other part\u00adners for approval in the USA.\u201d Says Michael Thiele, Invest\u00adment Man\u00adager at bm|t. Women who have abnor\u00admal find\u00adings from cer\u00advi\u00adcal can\u00adcer screen\u00ading can talk to their gyne\u00adcol\u00ado\u00adgist about Gyn\u00adTect or con\u00adtact oncg\u00adnos\u00adtics directly: <\/p>\n

kontakt@oncgnostics.com<\/a><\/p>\n

+493641 5548500<\/a><\/p>\n

 <\/p>\n

About oncg\u00adnos\u00adtics GmbH:<\/strong><\/p>\n

Jena-based oncg\u00adnos\u00adtics GmbH spe\u00adcial\u00adizes in the early detec\u00adtion of can\u00adcer. Its tests detect changes that are char\u00adac\u00adter\u00adis\u00adtic of the DNA of can\u00adcer cells. Founded in 2012, the com\u00adpany launched Gyn\u00adTect on the mar\u00adket in 2015. oncg\u00adnos\u00adtics GmbH is also research\u00ading clar\u00adi\u00adfi\u00adca\u00adtion tests for other types of can\u00adcer. You can find detailed infor\u00adma\u00adtion at www.oncgnostics.com.<\/a> <\/p>\n

Free image mate\u00adr\u00adial: www.tower-pr.com\/oncgnostics<\/a><\/p>\n

About GeneoDx and SINOPHARM Group:<\/strong><\/p>\n

GeneoDx is a sub\u00adsidiary of Sinopharm Group (China National Phar\u00adma\u00adceu\u00adti\u00adcal Group Co Ldt.). As one of the coun\u00adtry\u2019s lead\u00ading health\u00adcare com\u00adpa\u00adnies, Sinopharm has estab\u00adlished a nation\u00adwide logis\u00adtics and dis\u00adtri\u00adb\u00adu\u00adtion net\u00adwork for phar\u00adma\u00adceu\u00adti\u00adcals, med\u00adical devices and equip\u00adment. From research and devel\u00adop\u00adment, man\u00adu\u00adfac\u00adtur\u00ading, dis\u00adtri\u00adb\u00adu\u00adtion to tech\u00adni\u00adcal and finan\u00adcial ser\u00advices, the Group cov\u00aders the entire spec\u00adtrum of the indus\u00adtry. Sinopharm is ranked 80th<\/sup> on the Global For\u00adtune list, has more than 120,000 employ\u00adees and a turnover of 103.2 bil\u00adlion euros in 2021. <\/p>\n

About bm|t beteili\u00adgungs\u00adman\u00adage\u00adment th\u00fcrin\u00adgen gmbh: <\/strong><\/p>\n

bm|t is one of the top addresses for invest\u00adments in Thuringia. The cap\u00adi\u00adtal entrusted to bm|t is invested prof\u00aditably in start-up teams and com\u00adpa\u00adnies in the Free State. This is how inno\u00adva\u00adtions and eco\u00adnomic growth are financed in Thuringia. bm|t cur\u00adrently man\u00adages nine funds with a total vol\u00adume of over EUR 360 mil\u00adlion and invests in inno\u00adv\u00ada\u00adtive com\u00adpa\u00adnies in almost all sec\u00adtors and in all phases of cor\u00adpo\u00adrate devel\u00adop\u00adment \u2014 both in the start-up and growth phases as well as in com\u00adpany suc\u00adces\u00adsion sit\u00adu\u00ada\u00adtions.<\/strong><\/p>\n

www.bm<\/u>-<\/u>t.com<\/u><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The Gyn\u00adTect cer\u00advi\u00adcal can\u00adcer screen\u00ading test is now avail\u00adable to doc\u00adtors and patients in China under an exclu\u00adsive license from our part\u00adner Sinopharm.<\/p>\n","protected":false},"author":2,"featured_media":13918,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[216],"tags":[176,210,202,171],"class_list":["post-13924","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-2022-en","tag-bm-t-en","tag-investeepartner","tag-press","tag-thuringia"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/13924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/comments?post=13924"}],"version-history":[{"count":1,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/13924\/revisions"}],"predecessor-version":[{"id":18224,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/13924\/revisions\/18224"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media\/13918"}],"wp:attachment":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media?parent=13924"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/categories?post=13924"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/tags?post=13924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}